Aurobindo Pharma (AUROPHARMA) — Announcement

📢 Key Event
US FDA inspection of Auro Peptides subsidiary concluded with one observation.

💡 Investor Takeaway
The inspection outcome does not threaten operations or regulatory standing.

Aurobindo Pharma announced that its subsidiary Auro Peptides completed a US FDA inspection in Telangana from August 17-21, 2026, ending with one observation on facility maintenance that does not affect data integrity or GMP compliance; corrective actions were initiated during the inspection and a formal response will follow.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Limited (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹97,238.86 Cr P/E: 26.4 ROE: 9.8% ROCE: 12.8% Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"How will the FDA observation impact future US peptide sales?" "What is the expected timeline for corrective action completion?" "How does this affect Aurobindo's overall GMP compliance rating?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 21 August 2026

IDFCFIRSTB IDFC First Bank Limited Announcement EQUITASBNK Equitas Small Finance Bank Limited Corporate Action GLOBE GLOBE ENTERPRISES (INDIA) LIMITED Corporate Action TEXINFRA Texmaco Infrastructure & Holdings Limited Annual Report DYNAMATECH Dynamatic Technologies Limited Annual Report XCHANGING Xchanging Solutions Limited Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd